



ORIGINAL

Routine invasive strategy in acute coronary syndrome patients with renal dysfunction. Results of the ARIAM-SEMICYUC registry[☆]



J. Latour-Pérez^{a,*}, V. Gómez-Tello^b, E. de-Miguel-Balsa^a,
A. Llamas-Álvarez^a, A. Carrillo-López^c, J.A. Sánchez-Román^d, J. Ruíz-Ruíz^e,
M.C. Martín-Rodríguez^f, C.J. Fernández-González^g, J.A. Fernández-Lozano^h,
C. Picazos Vicente^a, Grupo ARIAM-SEMICYUC[◇]

^a Hospital General Universitario de Elche, Elche, Alicante, Spain

^b Hospital Moncloa, Madrid, Spain

^c Hospital Universitari Son Espases, Palma de Mallorca, Spain

^d Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain

^e Hospital General de Castelló, Castelló, Spain

^f Hospital General Universitario de Ciudad Real, Ciudad Real, Spain

^g Hospital Universitario Arquitecto Marcide-Nova Santos, Ferrol, La Coruña, Spain

^h Complejo Hospitalario Universitario de Cartagena, Cartagena, Murcia, Spain

Received 7 July 2015; accepted 24 September 2015

KEYWORDS

Percutaneous coronary intervention;
Acute coronary syndrome;
Renal dysfunction;
Mortality;
Registries

Abstract

Objective: To evaluate the use and effectiveness of a routine invasive strategy (RIS) in patients with acute coronary syndrome without persistent ST-segment elevation with renal dysfunction in the real world scenario.

Methods: A retrospective cohort study based on the ARIAM-SEMICYUC Registry (2011–2014) was carried out. Renal dysfunction was defined as GFR (Cockcroft–Gault) <60 ml/min (moderate dysfunction) or <30 ml/min (severe dysfunction). Patients in which early angiography (<72 h) was performed due to cardiogenic shock or recurrent myocardial ischemia were excluded. The primary endpoint was hospital mortality. Confounding factors were controlled using propensity score analysis.

Results: A total of 4279 patients were analyzed, of which 26% had moderate renal dysfunction and 5% severe dysfunction. Patients with renal dysfunction had greater severity and comorbidity, higher hospital mortality (8.6 vs. 1.8%), and lesser use of the RIS (40 vs. 52%). The adjusted

[☆] Please cite this article as: Latour-Pérez J, Gómez-Tello V, de-Miguel-Balsa E, Llamas-Álvarez A, Carrillo-López A, Sánchez-Román JA, et al. Estrategia invasiva de rutina en el síndrome coronario agudo sin elevación del segmento ST con disfunción renal. Resultados del registro ARIAM-SEMICYUC. Med Intensiva. 2016;40:280–288.

* Corresponding author.

E-mail address: jlatour@coma.es (J. Latour-Pérez).

◇ The list of members of the ARIAM-SEMICYUC Group are presented in the Annex.

OR for mortality in patients without/with renal dysfunction were 0.38 (95% confidence interval [95%CI] 0.17–0.81) and 0.52 (95%CI 0.32–0.87), respectively (interaction p -value = .4779). The impact (adjusted risk difference) of RIS was higher in the group with renal dysfunction (–5.1%, 95%CI –8.1 to –2.1 vs. –1.6%, 95%CI –2.6 to –0.6; interaction p -value = .0335). No significant interaction was detected for the other endpoints considered (ICU mortality, 30-day mortality, myocardial infarction, acute renal failure or moderate/severe bleeding).

Conclusions: The results suggest that the effectiveness of IRS is similar in patients with normal or abnormal renal function, and alert to the under-utilization of this strategy in such patients.

© 2016 Published by Elsevier España, S.L.U.

PALABRAS CLAVE

Intervención coronaria percutánea; Síndrome coronario agudo; Disfunción renal; Mortalidad; Registros

Estrategia invasiva de rutina en el síndrome coronario agudo sin elevación del segmento ST con disfunción renal. Resultados del registro ARIAM-SEMICYUC

Resumen

Objetivo: Evaluar la utilización y efectividad de la estrategia invasiva de rutina (EIR) en pacientes con síndrome coronario agudo sin elevación de ST con disfunción renal en el mundo real.

Métodos: Estudio de cohortes retrospectivo basado en el registro ARIAM-SEMICYUC (años 2011–2014). Se consideró que había disfunción renal cuando el GFR (Cockcroft-Gault) era menor de 60 ml/min (disfunción moderada) o de 30 ml/min (disfunción grave). Se excluyeron los pacientes en los que la coronariografía precoz (< 72 h) se debió a shock cardiogénico o isquemia recurrente. El desenlace primario fue la mortalidad hospitalaria. El control del *confounding* se realizó mediante un análisis de propensión.

Resultados: Se analizan 4.279 pacientes, de los cuales un 26% tenía disfunción renal moderada y un 5% disfunción grave. Los pacientes con disfunción renal presentaron una mayor gravedad y comorbilidad, una mayor mortalidad hospitalaria (8,6 frente a 1,8%) y una menor utilización de la EIR (40 frente a 52%). Las OR ajustadas mediante emparejamiento para pacientes sin/con disfunción renal fueron de 0,38 (intervalo de confianza al 95% [IC95%] de 0,17 a 0,81) y 0,52 (IC95% de 0,32 a 0,87), respectivamente (p de interacción 0,4779). El impacto de la EIR (diferencia de riesgos ajustada) fue mayor en el grupo con disfunción renal (–5,1%, IC95% entre –8,1 y –2,1, frente a –1,6%, IC95% entre –2,6 y –0,6, p de interacción = 0,0335). Tampoco se detectó interacción significativa respecto a los demás enlaces considerados (mortalidad en UCI o a los 30 días, riesgo combinado de muerte o infarto, fracaso renal agudo o hemorragias moderadas/graves).

Conclusiones: Los resultados evidencian que la efectividad de la EIR es similar en pacientes con función renal normal o reducida y alertan sobre una infrautilización de esta estrategia en estos últimos.

© 2016 Publicado por Elsevier España, S.L.U.

Patients presenting non-ST-segment elevation acute coronary syndrome (NSTE-ACS) with chronic renal dysfunction constitute a subgroup of individuals with a high mortality rate and an important risk of cardiac adverse events.^{1–8} Although the main clinical guides advocate the use of invasive management strategies in moderate-high risk patients^{9,10} the scientific literature consistently reflects a lesser utilization of invasive techniques in patients with NSTE-ACS and renal dysfunction.^{11–14}

This discrepancy between the recommendations of the guides and routine clinical practice could be related to the uncertainty regarding the benefit-risk ratio of an early invasive strategy in patients with chronic renal failure. In effect, a metaanalysis of randomized trials on routine invasive strategies (RIS) versus conservative management in patients with a glomerular filtration rate (GFR) estimated

using the Cockcroft–Gault method of <60 ml/min was only able to demonstrate a nonsignificant tendency toward lesser mortality with RIS.¹⁵ The problem of imprecision was greater in the subgroup of patients with severe renal dysfunction. In addition to these limitations, mention must be made of the risk of bias of the individual studies (characterized by a high cross-over rate) and the period in which they were carried out. In effect, a large proportion of the publications correspond to a period when many of the current antithrombotic agents and interventional technologies were not yet available; as a result, these results could be regarded as representing “indirect evidence”.¹⁶ On the other hand, it is well known that observational studies^{1,3,6,8,13,17,18} are hampered by confounding by indication. Although some studies address this problem through propensity score matching, in many cases the methodology used is not fully clear.

The present study uses data from a hospital acute coronary syndrome (ACS) registry to evaluate the frequency of use and the impact of RIS versus an initial conservative strategy in patients with NSTEMI-ACS, according to the degree of renal dysfunction.

Methods

Patients

The study was based on data from the ARIAM-SEMICYUC registry,¹⁹ a voluntary registry of consecutive patients admitted to Spanish Coronary Units or Intensive Care Units (ICUs) with a diagnosis of ACS and over 18 years of age, with less than 48 h from symptoms onset, and followed-up on until hospital discharge and (optionally) until 30 days from symptoms onset. Data compilation in the registry is carried out via annual cross-sectional sampling covering a period of three months. In addition, those centers that so wish can enter their own data over the full length of the year (continuous registry). A total of 76 centers participated during the study period; most corresponded to medium-size hospitals (Annex available in the online version), with the inclusion of an average of 49 patients per center. The study complied with Spanish legislation on data protection and the conduction of observational studies. The Ethics Committee did not consider it necessary to obtain patient informed consent.

In the present study we analyzed the patients included in the ARIAM-SEMICYUC registry between January 2011 and September 2014 with a diagnosis of NSTEMI-ACS. Patients admitted with cardiogenic shock (in which an urgent invasive strategy is recommended⁹) were excluded, as were those patients subjected to urgent coronarography due to shock or recurrent pain in the initial 72 h following first contact with medical care.

Measurements

The patients were considered exposed if coronariography had been performed within the first 72 h, and as non-exposed if otherwise. According to the established cutoff points, the patients were subclassified into three renal function groups: normal function (glomerular filtration rate [GFR] estimated with the Cockcroft-Gault method²⁰ ≥ 60 ml/min), moderate dysfunction (GFR 30–59 ml/min) or severe dysfunction (GFR < 30 ml/min).

The primary endpoint was in-hospital mortality. Secondary endpoints were mortality in the ICU and after 30 days, the appearance of infarction or reinfarction, moderate-severe hemorrhage (based on criteria of the GUSTO study²¹), and the appearance of acute renal failure (defined as a rise in creatinine to 1.5 times the baseline value, or diuresis < 0.5 ml/kg during 6 h).

The following potential confounding factors were considered: demographic data (age, gender), care parameters (form of access, transport and delays in access to the center, availability of cardiac catheterization²²), coronary risk factors, previous cardiovascular disease, previous treatments (pharmacological and coronary) and baseline clinical condition (blood pressure, heart rate, initial ECG tracing, initial

Killip score,²³ TIMI score,²⁴ GRACE score²⁵ and CRUSADE score²⁶) (Tables 1 and 2).

Statistical analysis

The effectiveness of RIS was examined by estimating the odds ratio (OR)–relative effect–and risk difference (RD)–absolute effect–with the corresponding 95% confidence intervals (95% CIs).

The control of confounding by indication was carried out via propensity score matching^{27,28} using the R²⁹ and Stats-Direct statistical packages.³⁰ To this effect, we created a propensity score at the time of RIS that included 33 variables available at the time of patient admission (see Table S4 of the supplementary material available in the online version). The odds ratio of the RIS referred to the different outcomes or endpoints was analyzed through 5 quintile-stratified analysis of the propensity score and paired cohorts analysis. The absolute effect (RD) was estimated from the results of the 5 quintile-stratified propensity analysis, weighted by the method of Greenland and Robins.³¹

This analytical procedure was carried out separately for the patients with moderate-severe renal dysfunction (GFR < 60 ml/min) and for those with normal renal function (GFR ≥ 60 ml/min). The differences of effect (raw and adjusted) between these two strata were contrasted using an interaction test based on the Cochran Q-statistic.

In addition, a post hoc subgroups analysis was made referred to the GRACE score (> 140 versus ≤ 140), gender (females versus males), and availability of hemodynamics (possibility or not of cardiac catheterization in the center).

Results

A total of 4363 patients were considered for inclusion in the study. Of these, 84 were excluded due to recurrent ischemia or cardiogenic shock. Of the 4279 patients finally analyzed, 69% had normal or slightly reduced renal function, 26% presented moderate renal dysfunction, and 5% had severe renal dysfunction. The observed in-hospital mortality rate was 1.8%, 8.4% and 9.6%, respectively ($p < 0.0001$) (Fig. 1).

In-hospital mortality could not be determined in 287 patients with normal renal function (9.8%) and in 130 patients with renal dysfunction (9.7%). The demographic characteristics, comorbidities and initial severity of the patients lost to follow-up did not differ appreciably from those of the patients that completed follow-up (see Table S3 of the supplementary material available in the online version).

The percentage of patients subjected to RIS in the subgroups of normal renal function, moderate renal dysfunction and severe renal dysfunction was 52%, 42% and 33%, respectively ($p < 0.0001$) (Fig. 1).

The baseline characteristics of the patient treated on an invasive or conservative basis were very different (Table 1). The conservative management group was characterized by patients preferentially admitted to hospitals without possibilities for hemodynamic testing, individuals of older age, with poorer renal function, an increased prevalence of

Table 1 Baseline characteristics of the patients.

	RIS (n = 2075)	ICS (n = 2204)	p-value
Age in years, mean (SD)	65.7 (12.6)	68.3 (12.5)	<0.0001
Gender (% females)	539 (26.0)	646 (29.3)	0.0148
Smoking	718 (34.6)	591 (26.8)	<0.0001
Arterial hypertension	532 (25.6)	597 (27.1)	0.2826
Dyslipidemia	1.135 (54.7)	1.276 (57.9)	0.0351
Diabetes mellitus	637 (30.7)	778 (35.3)	0.0014
Previous myocardial infarction	469 (22.6)	618 (28.0)	<0.0001
Arterial disease	175 (8.4)	233 (10.6)	0.0173
Previous heart failure	79 (3.8)	192 (8.7)	<0.0001
COPD	202 (9.7)	257 (11.7)	0.0419
History of bleeding	38 (1.8)	77 (3.5)	0.0008
Known coronary lesions	444 (21.4)	570 (25.9)	0.0006
Previous aspirin use	697 (33.6)	867 (39.3)	<0.0001
Previous use other antiplatelet drugs	299 (14.4)	379 (17.2)	0.0126
Previous use beta-blockers	544 (26.2)	704 (31.9)	<0.0001
Previous use ACEIs	868 (41.8)	1004 (45.6)	0.0142
Previous use lipid-lowering drugs	892 (43.0)	1102 (50.0)	<0.0001
Previous use diuretics	365 (17.6)	521 (22.6)	<0.0001
Previous use nitrates	210 (10.1)	346 (15.7)	<0.0001
Year			
2011	275 (13.3)	482 (21.9)	<0.0001
2012	542 (26.1)	573 (26)	
2013	707 (34.1)	654 (29.7)	
2014	551 (26.6)	495 (22.5)	
Availability of hemodynamics	900 (43.4)	514 (23.3)	<0.0001
Private hospital	99 (4.8)	221 (10.0)	<0.0001
First medical care contact			
Hospital emergency room	1011 (48.7)	1019 (46.2)	0.0015
112/061	255 (12.3)	302 (13.7)	
Primary care center	585 (28.2)	575 (26.1)	
Hospitalized	92 (4.4)	154 (7.0)	
Others	132 (6.4)	154 (7.0)	
Delay in minutes, mean (SD)	681.8 (518.9)	627.5 (499.7)	<0.0001
Glomerular filtration rate (Cockcroft), mean (SD)	85.6 (37.1)	76.4 (35.7)	<0.0001
Initial systolic blood pressure, mean (SD)	140.0 (27.7)	140.0 (26.3)	0.7744
Initial diastolic blood pressure, mean (SD)	76.5 (16.5)	77.1 (15.5)	0.2113
Initial heart rate, mean (SD)	80.8 (21.5)	77.6 (19.2)	<0.0001
ECG upon admission			
Normal	235 (11.3)	281 (12.8)	<0.0001
ST deviation >0.5 mm	560 (27.0)	544 (24.7)	
ST deviation <0.5 mm	251 (12.1)	281 (12.8)	
Transient ST deviation	193 (9.3)	13 (5.9)	
T-wave inversion	421 (20.3)	433 (19.7)	
Trunk/multiple vessel pattern	77 (3.7)	42 (1.9)	
Others	338 (16.3)	492 (22.3)	
Initial Killip score			
1	1744 (84.1)	1591 (72.2)	<0.0001
2	216 (10.4)	355 (16.1)	
3	115 (5.5)	258 (11.7)	
TIMI score			
0–1	45 (2.2)	41 (1.9)	<0.0001
1	479 (23.1)	382 (17.3)	
2	671 (32.3)	742 (33.7)	
3	461 (22.2)	490 (22.2)	
4	275 (13.3)	356 (16.2)	
5	122 (5.9)	157 (7.1)	
6–7	22 (1.1)	36 (1.6)	
GRACE score, mean (SD)	133.3 (36.6)	142.2 (40.4)	<0.0001
CRUSADE score, mean (SD)	41.3 (17.9)	37.9 (17.4)	<0.0001

SD: standard deviation; ECG: electrocardiogram; ICS: initial conservative strategy; RIS: routine invasive strategy; COPD: chronic obstructive pulmonary disease; ACEIs: angiotensin converting enzyme inhibitors.

Values reported as n (percentage), except where stated otherwise.

Table 2 Standardized differences in the original cohorts and in the matched cohorts.

Variable	GFR < 60 ml/min		GFR ≥ 60 ml/min	
	Original cohorts	Matched cohorts	Original cohorts	Matched cohorts
Age	2.139	1.274	17.638	12.827
Gender	8.126	5.786	5.226	7.504
Arterial hypertension	4.191	1.643	6.772	4.171
Dyslipidemia	9.472	2.46	4.201	2.628
Diabetes	7.478	0.811	5.563	2.15
Previous infarction	5.424	0	10.867	4.04
Arterial disease	8.186	0.586	3.237	2.808
Heart failure	24.099	5.715	13.52	6.18
COPD	9.862	2.308	3.918	5.979
History of bleeding	10.13	5.173	7.095	2.079
Known coronary lesions	5.34	0.872	9.443	3.069
Previous aspirin use	8.732	1.216	8.556	2.244
Previous use other antiplatelet drugs	0.935	2.838	5.231	1.605
Previous use nitrates	11.359	5.086	16.322	7.572
Previous use beta-blockers	8.463	5.003	11.572	6.059
Previous use ACEIs	0.159	1.612	6.341	4.339
Previous use lipid-lowering drugs	13.194	7.267	9.909	4.636
Previous use diuretics	9.039	4.248	11.529	5.668
Year	3.989	4.359	17.928	16.368
Availability of hemodynamics	43.997	26.012	38.535	46.102
Private hospital	26.862	0	7.116	8.313
First contact	7.724	3.395	5.893	7.54
Delay	9.565	5.323	10.715	9.646
Glomerular filtration	13.758	4.142	13.684	10.497
Systolic blood pressure	4.662	3.733	4.284	5.174
Diastolic blood pressure	2.913	3.732	1.769	0.721
Heart rate	14.498	3.646	12.124	7.873
Normal initial ECG	6.195	4.736	2.445	0.262
ST deviation >0.5 mm	0.613	2.179	10.508	11.492
ST deviation <0.5 mm	3.6	3.463	6.308	4.423
Transient ST deviation	6.45	2.37	14.365	15.87
T-wave inversion	4.331	7.197	1.972	5.014
Trunk/multiple vessel pattern	11.192	7.244	9.818	11.682
Killip score	31.888	12.878	15.435	6.466
TIMI score	5.677	1.357	10.07	3.407
GRACE score	20.393	8.443	10.825	2.992
CRUSADE score	26.452	9.784	6.788	0.435

ECG: electrocardiogram; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate; ACEIs: angiotensin converting enzyme inhibitors.

diabetes and known ischemic heart disease, a lesser prevalence of high risk ECG findings, and greater initial severity as established from the Killip, TIMI or GRACE scores.

Propensity score matching of the cohorts yielded 1144 matched pairs with normal renal function and 499 with renal dysfunction. The distribution of the propensity scores in the invasive and conservative management groups showed adequate overlap (see Figure S1 of the supplementary material available in the online version). Propensity score matching was largely able to homogenize both populations (see Table S2 of the supplementary material available in the online version), though standardized differences of over 10 persisted in relation to some variables of little prognostic impact in both the subgroup with renal dysfunction and in the subgroup with normal renal function.

Regarding the primary endpoint, the effect of RIS was similar in patients with moderate-severe dysfunction (adjusted OR 0.52; 95%CI 0.32–0.87) and normal renal function (adjusted OR 0.38; 95%CI 0.17–0.81) (interaction test $p=0.4779$). Likewise, no interaction was observed between RIS and the degree of renal function on stratifying into three groups (interaction test $p=0.76$) (see Figure S3 of the supplementary material available in the online version).

Given the different baseline risk, the risk difference was greater in the group of patients with renal dysfunction (RD -5.1% ; 95%CI -8.1 to -2.1) than in the group with preserved renal function (RD -1.6% ; 95%CI -2.6 to -0.6) (interaction test $p=0.0335$) (Tables 3 and 4; Fig. 2).

Regarding the secondary endpoints, RIS was associated to a decrease in mortality in the ICU and after 30 days, with no

Table 3 Effectiveness of the routine invasive strategy (raw and adjusted odds ratios).

	GFR < 60	GFR ≥ 60	Interaction <i>p</i> -value
<i>M ICU</i>			
ORr (95%CI)	0.3734 (0.1781 to 0.7271)	0.3973 (0.1758 to 0.8411)	0.8996
ORa (95%CI)	0.44 (0.2165 to 0.8941)	0.45 (0.2049 to 0.9882)	0.9668
ORas (95%CI)	0.4224 (0.209 to 0.8537)	0.444 (0.2048 to 0.9626)	0.9255
<i>M Hosp</i>			
ORr (95%CI)	0.4148 (0.26520 to 0.6352)	0.3814 (0.1971 to 0.7071)	0.8196
ORa (95%CI)	0.5227 (0.3157 to 0.8655)	0.375 (0.1743 to 0.8066)	0.4779
ORas (95%CI)	0.4579 (0.2736 to 0.7662)	0.3392 (0.1679 to 0.6852)	0.4998
<i>M30</i>			
ORr (95%CI)	0.4655 (0.2954 to 0.7204)	0.3466 (0.1904 to 0.609)	0.3999
ORa (95%CI)	0.549 (0.3462 to 0.8706)	0.4412 (0.2403 to 0.8099)	0.5743
ORas (95%CI)	0.5578 (0.3493 to 0.8907)	0.3928 (0.218 to 0.7077)	0.3608
<i>AMI reinf</i>			
ORr (95%CI)	0.6359 (0.3104 to 1.2405)	1.0084 (0.5927 to 1.7217)	0.2634
ORa (95%CI)	0.52 (0.266 to 1.0164)	1 (0.5807 to 1.7222)	0.1375
ORas (95%CI)	0.7 (0.3649 to 1.343)	1.1881 (0.7 to 2.0164)	0.2166
<i>ARF</i>			
ORr (95%CI)	0.7522 (0.5148 to 1.0893)	0.6075 (0.2846 to 1.2584)	0.5855
ORa (95%CI)	0.7213 (0.4895 to 1.0629)	0.5789 (0.2755 to 1.2166)	0.6069
ORas (95%CI)	0.8247 (0.5625 to 1.2092)	0.7659 (0.3597 to 1.6307)	0.8641
<i>Hemorr</i>			
ORr (95%CI)	0.6447 (0.3285 to 1.2165)	0.6407 (0.2756 to 1.45)	0.9901
ORa (95%CI)	0.7143 (0.3682 to 1.3856)	0.7857 (0.3567 to 1.7307)	0.8563
ORas (95%CI)	0.844 (0.4366 to 1.6313)	0.648 (0.2902 to 1.4473)	0.6182

GFR: glomerular filtration rate; ARF: acute renal failure; Hemorr: moderate-severe hemorrhage; AMI reinf: infarction or reinfarction; 95%CI: 95% confidence interval; M Hosp: in-hospital mortality; M ICU: mortality in the Coronary Unit; M30: mortality after 30 days; ORr: raw odds ratio; ORa: matching adjusted odds ratio; ORas: stratification adjusted odds ratio.

Table 4 Impact of the routine invasive strategy (raw and adjusted risk differences).

	GFR < 60	GFR ≥ 60	Interaction <i>p</i> -value
<i>M ICU</i>			
RDr (95%CI)	-4.81% (-7.26 to -2.34)	-0.95% (-1.38 to -0.13)	0.0004
RDa (95%CI)	-2.92% (-5.02 to -0.83)	-0.89% (-1.7 to -0.09)	0.0763
<i>M Hosp</i>			
RDr (95%CI)	-7.55% (-10.79 to -4.25)	-1.79% (-2.97 to -0.75)	0.0001
RDa (95%CI)	-5.06% (-8.05 to -2.07)	-1.64% (-2.64 to -0.64)	0.0335
<i>M30</i>			
RDr (95%CI)	-0.0799 (-0.1211 to -0.0378)	-0.032 (-0.0494 to -0.0165)	0.0364
RDa (95%CI)	-0.0559 (-0.0974 to -0.0144)	-0.0262 (-0.0419 to -0.0105)	1895
<i>AMI reinf</i>			
RDr (95%CI)	-0.0142 (-0.0335 to 0.0062)	0.0002 (-0.0107 to 0.0108)	0.9524
RDa (95%CI)	-0.0123 (-0.0346 to 0.0101)	0.0036 (-0.0074 to 0.0146)	0.2109
<i>ARF</i>			
RDr (95%CI)	-0.0273 (-0.0603 to 0.0072)	-0.0058 (-0.0145 to 0.0021)	0.2253
RDa (95%CI)	-0.0185 (-0.0551 to 0.018)	-0.0028 (-0.0099 to 0.0044)	0.4087
<i>Hemorr</i>			
RDr (95%CI)	-0.0165 (-0.0387 to 0.0066)	-0.0045 (-0.0132 to 0.0032)	0.3289
RDa (95%CI)	-0.006 (-0.0283 to 0.0163)	-0.0043 (-0.0121 to 0.0034)	0.8878

GFR: glomerular filtration rate; RDa: adjusted risk differences; RDr: raw risk differences; ARF: acute renal failure; Hemorr: moderate-severe hemorrhage; AMI reinf: infarction or reinfarction; 95%CI: 95% confidence interval; M Hosp: in-hospital mortality; M ICU: mortality in the Coronary Unit; M30: mortality after 30 days.




Figure 1 In-hospital mortality and routine invasive strategy (RIS) utilization according to baseline risk.




Figure 2 Raw and adjusted in-hospital mortality differences.

significant reduction in the risk of infarction/reinfarction, acute renal failure or moderate-severe hemorrhage. The effect for these 5 endpoints was similar (interaction test p =nonsignificant) for the patients with and without renal dysfunction (Table 3).

The analysis of subgroups showed that within the stratum of patients with a GRACE score >140, RIS reduced in-hospital mortality both in patients with renal dysfunction and in those with normal renal function. In the patients with a GRACE score ≤140, RIS did not significantly reduce in-hospital mortality. The interaction test p -value was not statistically significant, however. The effectiveness of RIS in patients with normal renal function was shown to be greater in centers without a Hemodynamics Unit than in those where hemodynamic testing was available (interaction test p =0.0133). There was no evidence of interaction between RIS application and patient gender in either patients with

normal renal function or in patients with altered renal function (see Table S5 of the supplementary material available in the online version).

Discussion

Our results confirm the persistent scant use of RIS in patients with NSTEMI-ACS and renal dysfunction, and show that this strategy is associated to a relative reduction of in-hospital mortality and mortality after 30 days in these patients, being comparable to that of patients with normal renal function.^{5,6,8,15,32} In absolute terms, however, the short-term reduction in mortality among patients with renal failure is greater than in those with normal renal function: on treating the same number of patients, the number of deaths avoided by RIS is greater in patients with renal dysfunction than in individuals with normal renal function.

On the other hand, we detected no association between the application of RIS and the incidence of infarction, renal failure or moderate-severe hemorrhage in patients with renal dysfunction. The absence of a detectable effect upon the risk of infarction is consistent with the observations of most published studies, which report an initial increase in infarction risk that is only compensated by a decrease in reinfarction risk over the middle to long term. In turn, the negative results referred to the risk of hemorrhage and renal failure could be due to both a lack of statistical power of the study and to improved preventive practices in this field (e.g., generalization of the radial access, or the prevention of contrast-induced nephropathy).

With regard to the reasons underlying lesser utilization of RIS in patients with renal dysfunction, concerns about causing contrast-induced nephropathy and additional impairment of renal function could dissuade clinicians from applying RIS in such cases. However, the impact of iodine contrast administration upon important endpoints or outcomes (such as death or the need for dialysis) has not been clearly established,³³ and the existing evidence points to a benefit-risk ratio favorable to the use of RIS in patients with renal failure.^{9,10}

From a broader perspective, the infra utilization of RIS in these patients could be regarded as a peculiar manifestation of a tendency among clinicians to avoid using invasive procedures in high risk patients.^{11,12,14,17} In our concrete case, the utilization of RIS predominantly corresponded to the subgroup of patients with normal renal function and a GRACE score <140, which is precisely the group that stands to benefit least from such treatment. The possible influence of difficulties in moving the patient to the catheterization room, and the limitation of vital support measures in the more seriously ill patients, requires more in depth studies.

Our study has limitations, including particularly its observational design. Although propensity score matching resulted in a uniform distribution of the main covariables between the experimental group and the control group, we cannot rule out the existence of residual confounding effects attributable to certain variables not included in the registry. This residual confounding effect could explain the differences between the odds ratios estimated by observational studies and those estimated from randomized trials—with clearly more favorable values in the former. An alternative explanation could be the strong cross-over presence in the randomized studies (patients in the control group subjected to percutaneous coronary intervention), which would contribute to underestimate the benefit of RIS. In any case, rather than establishing a point estimation of the effect of RIS, our study sought to explore the possible heterogeneity of effects according to the degree of renal functional impairment.

Another limitation of our study refers to the losses to follow-up and the lack of middle-long term results. The credibility of our findings is strengthened by the absence of systematic differences between the patients lost to follow-up and those included in the study, as well as by the consistency of our results with those of other studies. Nevertheless, the possible existence of selection bias cannot be ruled out entirely.

Lastly, although we detected no subgroup effect in the patients with severe renal dysfunction, a total of 16 events

were recorded among these subjects. Our study therefore has a problem of imprecision in estimating the effect in patients with severe renal dysfunction.³⁴

In conclusion, the results obtained indicate that the effectiveness of RIS is similar in patients with normal or impaired renal function, and alert to infrautilization of this strategy among the latter type of patients.

Financial support

SEMICYUC.

Conflict of interest

None.

Annex. Supplementary data

Supplementary material associated with this article can be found in the online version available at: <http://dx.doi.org/10.1016/j.medin.2015.09.008>.

References

1. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. *Am J Cardiol.* 2003;92:509–14.
2. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. *JAMA.* 2004;292:2096–104.
3. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA. Survival after coronary revascularization among patients with kidney disease. *Circulation.* 2004;110:1890–5.
4. El-Menyar A, Zubaid M, Sulaiman K, Singh R, Al Thani H, Akbar M, et al. In-hospital major clinical outcomes in patients with chronic renal insufficiency presenting with acute coronary syndrome: data from a Registry of 8176 patients. *Mayo Clin Proc.* 2010;85:332–40.
5. Goldenberg I, Subirana I, Boyko V, Vila J, Elosua R, Permanyer-Miralda G, et al. Relation between renal function and outcomes in patients with non-ST-segment elevation acute coronary syndrome: real-world data from the European Public Health Outcome Research and Indicators Collection Project. *Arch Intern Med.* 2010;170:888–95.
6. Hachinohe D, Jeong MH, Saito S, Ahmed K, Hwang SH, Lee MG, et al. Management of non-ST-segment elevation acute myocardial infarction in patients with chronic kidney disease (from the Korea Acute Myocardial Infarction Registry). *Am J Cardiol.* 2011;108:206–13.
7. Hanna EB, Chen AY, Roe MT, Wiviott SD, Fox CS, Saucedo JF. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. *JACC Cardiovasc Interv.* 2011;4:1002–8.
8. Shaw C, Nitsch D, Steenkamp R, Junghans C, Shah S, O'Donoghue D, et al. Inpatient coronary angiography and revascularisation following non-ST-elevation acute coronary syndrome in patients with renal impairment: a cohort study using the Myocardial Ischaemia National Audit Project. *PLOS ONE.* 2014;9:e99925.

9. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;130:2354–94.
10. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2011;32:2999–3054.
11. Latour-Pérez J, Fuset-Cabanes MP, Ruano Marco M, del Nogal Sáez F, Felices Abad FJ, Cuñat de la Hoz J, Grupo ARIAM. Uso de la estrategia invasiva precoz en el síndrome coronario agudo sin elevación de ST. La paradoja continúa. *Med Intensiva*. 2012;36:95–102.
12. Jedrzkiewicz S, Goodman SG, Yan RT, Welsh RC, Kornder J, DeYoung JP, et al. Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. *Can J Cardiol*. 2009;25:e370–6.
13. Ferreira-González I, Permanyer-Miralda G, Heras M, Cuñat J, Civeira E, Arós F, et al. Patterns of use and effectiveness of early invasive strategy in non-ST-segment elevation acute coronary syndromes: an assessment by propensity score. *Am Heart J*. 2008;156:946–53, 953.e2.
14. Yan AT, Yan RT, Tan M, Eagle KA, Granger CB, Dabbous OH, et al. In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. *Am J Cardiol*. 2005;96:913–6.
15. Charytan DM, Wallentin L, Lagerqvist B, Spacek R, de Winter RJ, Stern NM, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. *Clin J Am Soc Nephrol*. 2009;4:1032–43.
16. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence – indirectness. *J Clin Epidemiol*. 2011;64:1303–10.
17. Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: a meta-analysis of individual patient data. *J Am Coll Cardiol*. 2010;55:2435–45.
18. Huang HD, Alam M, Hamzeh I, Virani S, Deswal A, Aguilar D, et al. Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. *Int J Cardiol*. 2013;168:3741–6.
19. SEMICYUC. Investigación. ARIAM; 2015. Available from: <http://www.semicyuc.org/temas/investigacion/registros/ariam> [accessed 30.03.15].
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16:31–41.
21. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation*. 2011;123:2736–47.
22. García del Blanco B, Hernández Hernández F, Rumoroso Cuevas JR, Trillo Nouche R. Registro Español de Hemodinámica y Cardiología Intervencionista XXIII Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990–2013). *Rev Esp Cardiol*. 2014;67:1013–23.
23. Siniorakis E, Arvanitakis S, Voyatzopoulos G, Hatziandreu P, Plataris G, Alexandris A, et al. Hemodynamic classification in acute myocardial infarction. *Chest*. 2000;117:1286–90.
24. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. *JAMA*. 2000;284:835–42.
25. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. *JAMA*. 2004;291:2727–33.
26. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. *Circulation*. 2009;119:1873–82.
27. Brookhart MA, Wyss R, Layton JB, Sturmer T. Propensity score methods for confounding control in nonexperimental research. *Circ Cardiovasc Qual Outcomes*. 2013;6:604–11.
28. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivariate Behav Res*. 2011;46:399–424.
29. Stampf S. Nonrandom: stratification and matching by the propensity score. R package version 1.42; 2014. Available from: <http://CRAN.R-project.org/package=nonrandom> (last accessed June 2015).
30. StatsDirect. StatsDirect statistical software. 3.0.146. Altrincham, Reino Unido: StatsDirect Ltd.; 2015.
31. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. *Biometrics*. 1985;41:55–68.
32. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). *Circulation*. 2009;120:851–8.
33. McDonald RJ, McDonald JS, Carter RE, Hartman RP, Katzberg RW, Kallmes DF, et al. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. *Radiology*. 2014;273:714–25.
34. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. *J Clin Epidemiol*. 2011;64:1283–93.